StockNews.AISignal intelligence

Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signalsAsk the Agent
TPSTBullishEarningsShort Term
High materiality8/10

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

StockNews.AIAug 13, 4:25 PM EDT1 source
Trading thesisImportance 8/10

Bullish on TPST into and shortly after Q4 2026 catalyst window; financing risk remains a watchpoint.

AI summary

What happened and why it matters

Tempest Therapeutics disclosed a collaboration with Hebei Senlang Biotechnology to advance TPST-4003, with first patient dosing expected in Q4 2026 and initial data in H1 2027. The company also highlighted TPST-2003 interim results showing 100% complete responses in 15 evaluable patients and a China-focused BD push, while cash runway remains tight and capital needs persist.

  • TPST-4003 collaboration with Senlang could unlock China development and partnerships.
  • First patient dosing for TPST-4003 expected in Q4 2026; data anticipated H1 2027.
  • TPST-2003 interim results (100% CR) support upside but small cohorts limit durability.
  • Cash runway- liquidity risk persists; potential dilutive financing or capital raises.

Sentiment rationale

Near-term TPST catalysts (TPST-4003 dosing, Senlang China trial, AGCTC manufacturing support) could drive upside despite liquidity risk; TPST-2003 interim efficacy supports upside if validated, though small cohorts limit durability.

Key facts

  1. 01

    TPST-4003: CD19/BCMA CAR-T via CD7 mRNA/LNP; first patient dosing Q4 2026.

  2. 02

    Senlang collaboration to run ~10-patient China trial in MG/MS; first patient Q4 2026.

  3. 03

    TPST-2003 interim: 100% CR in 15 efficacy-evaluable patients; favorable safety.

  4. 04

    Q2 cash shows $0.8m; cash burn rising; asset acquisition and warrants affected liquidity.

Corporate Developments

Category: Corporate Developments. The release combines pipeline updates with strategic partnerships, governance changes, and financing activity—key drivers of near-term sentiment and potential valuation inflection for TPST.

More AI-analyzed coverage connected to this story